Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 17/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4335098 | 0.79 | BRD4 (0.41) | TNFLMNAGAARAB9A | |
| SCHEMBL4336675 | 0.77 | TNF (0.49) | TNF | |
| SCHEMBL4326562 | 0.75 | TNF (0.41) | TNFKDM4EGAAHPGDRAB9A | |
| SCHEMBL4344210 | 0.72 | BRD4 (0.43) | LMNAKDM4EHPGDRAB9AHSD17B10 | |
| SCHEMBL13783392 | 0.72 | TNF (0.42) | TNFGAA | |
| SCHEMBL13783395 | 0.69 | TNF (0.38) | TNFKDM4EGAAHPGDRAB9A | |
| SCHEMBL9533319 | 0.68 | HPRT1 (0.64) | HPRT1 | |
| SCHEMBL4328650 | 0.68 | TNF (0.42) | TNFGAA | |
| SCHEMBL12657435 | 0.66 | LMNA (0.85) | TNFLMNAKDM4EGAA | |
| SCHEMBL23959823 | 0.66 | TNF (0.48) | TNFLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1661897-B1 | PYRROLOPYRIMIDINONE DERIVATIVE | TEIJIN PHARMA LTD (JP) | 2013-12-04 | — | — | EP | disclosed |
| US-7557113-B2 | Substituted pyrrolo[3,2-d]pyrimidine derivatives | TEIJIN PHARMA LIMITED (JP) | 2009-07-07 | — | — | US | disclosed |
| US-7557113-B2 | Substituted pyrrolo[3,2-d]pyrimidine derivatives | TEIJIN PHARMA LIMITED (JP) | 2009-07-07 | — | — | US | disclosed |
| US-7557113-B2 | Substituted pyrrolo[3,2-d]pyrimidine derivatives | TEIJIN PHARMA LIMITED (JP) | 2009-07-07 | — | — | US | disclosed |
| US-20060160831-A1 | Pyrrolopyrimidinone derivatives | TEIJIN PHARMA LIMITED (JP) | 2006-07-20 | — | — | US | disclosed |
| EP-1661897-A1 | PYRROLOPYRIMIDINONE DERIVATIVE | Teijin Pharma Limited (JP) | 2006-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160831-A1 | Pyrrolopyrimidinone derivatives | GSK3B, GSK3A, GSKIP | TNF 3687/4885LMNA 863/4885KDM4E 1531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.